Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (US)
Agents for treating major depressive disorder (MDD) span multiple drug classes; while selective serotonin reuptake inhibitors (SSRIs) and serotonin / norepinephrine reuptake inhibitors (SNRIs) are considered the standards of care, branded therapies, including Trintellix (Lundbeck’s vortioxetine) and Spravato (J&J Innovative Medicine’s esketamine), are important treatment alternatives, particularly for treatment-resistant depression (TRD). Given the highly genericized nature of the MDD therapy market, the differences in the availability of drugs in the United States, the heterogeneity of the MDD patient population, and patients’ varied responses to treatment, the prescribing pattern of U.S. psychiatrists and primary care physicians (PCPs) can vary. Understanding the decision points and challenges that physicians face when treating MDD is paramount for marketers of current therapies and developers of emerging therapies to assess the opportunities for drug development in this highly prevalent indication.
Questions answered
- What are the drivers and constraints influencing physicians’ treatment decisions for MDD?
- How are patients being treated in various lines of therapy, and what is the patient share of individual therapies?
- What percentage of drug-treated MDD patients are partial responders, and what percentage are treatment-resistant? What is the most common course of action for partial responders and TRD patients?
- What drives switching to and from key brands (e.g., Trintellix, Spravato, Auvelity)?
- To what extent is polypharmacy used for MDD in different lines of therapy in the United States?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:
- Understand the treatment landscape for a disease and how physicians make prescribing decisions.
- Evaluate the drivers and obstacles that influence treatment selection.
Geography: United States
Primary research: Survey of 50 U.S. PCPs and 52 U.S. psychiatrists
Key companies: Johnson & Johnson Innovative Medicine, Lundbeck, Otsuka, Takeda, Axsome Therapeutics, AbbVie
Key drugs: Trintellix, Rexulti, Vraylar, Spravato, Auvelity, sertraline, escitalopram, bupropion, duloxetine
Key analyses
- Factors influencing disease management and treatment decisions
- Drivers and constraints of treatment selection
- Physician-reported treatment practices and brand-level patient shares
- Rationale for changes in treatment approach
- Physician insight on persistency and compliance
- Physician-reported recent / anticipated changes in brand usage or treatment approach
